Astrazeneca (AZN) Non-cash Items (2009 - 2026)

Astrazeneca (AZN) has reported Non-cash Items for 18 consecutive years, with $4.3 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Non-cash Items fell 3.82% year-over-year to $4.3 billion; the TTM figure through Mar 2026 stood at $4.3 billion (down 3.82% YoY), while the FY2025 annual figure was $18.7 billion, up 17.66% from the prior year.
• Non-cash Items came in at $4.3 billion for Q1 2026 at Astrazeneca, down from $18.7 billion in the prior quarter.
• The five-year high for Non-cash Items was $18.7 billion in Q4 2025, with the low at $3.3 billion in Q1 2024.
• Average Non-cash Items over 5 years is $8.5 billion, with a median of $6.4 billion recorded in 2023.
• Across the five-year window, Non-cash Items surged 88.53% in 2022 and slipped 9.9% in 2024, its largest moves.
• Year by year, Non-cash Items stood at $5.9 billion in 2022, then climbed by 8.91% to $6.4 billion in 2023, then jumped by 149.01% to $15.9 billion in 2024, then climbed by 17.66% to $18.7 billion in 2025, then sank by 76.91% to $4.3 billion in 2026.
• According to Business Quant data, Non-cash Items over the past three periods registered $4.3 billion, $18.7 billion, and $15.5 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.